Ainult tellijatele

10. detsember 2006

Ainult tellijatele

Tähelepanu! Artikkel on enam kui 5 aastat vana ning kuulub väljaande digitaalsesse arhiivi. Väljaanne ei uuenda ega kaasajasta arhiveeritud sisu, mistõttu võib olla vajalik kaasaegsete allikatega tutvumine.

Houston TX- USA and Calabasas Hills- CA- USA - December 11- 2006 - Stem Cell Innovations- Inc. (SCLL.OB) and The ALS Association- a non-profit health organization dedicated to finding a cure for amyotrophic lateral sclerosis (ALS)- announced today a two-year discovery alliance. Stem Cell Innovations (SCI) will develop human motor neuron models based on its proprietary PluriCell(TM) technology that can be used for high-throughput screening. Subsequently- the cell models will be used by alliance partner Galapagos to discover novel drug targets for ALS. Under the terms of the agreement- SCI will receive 400-000 Euros ($512-000) from The ALS Association- upon completion of certain milestones. In addition- SCI has the option to further develop certain cell-therapy applications based on results identified in the program.

"The human motor neuron cultures derived from our PluriCellswill form the basis of this exciting alliance-" said Stem CellInnovations CEO Dr. James Kelly. "We are very pleased to becollaborating with The ALS Association and Galapagos on thisdiscovery project."